Hepatitis B Disease Monitoring Profile
|
$133
|
|
|
Description:
Hepatitis B is a liver disease that is caused by the Hepatitis B Virus (HBV). This panel is designed for monitoring the progression of treatment of infected individuals.
Significant deviations from the normal range may require further evaluation by your physician.
Includes:
Hep B Core Antibody, IgM
Hepatitis B Surface Antibody Immunity, Quantitative
Hepatitis B Surface Antigen (HBsAg) with Reflex Confirmation
Liver Function Profile: Alanine aminotransferase (ALT/SGPT); albumin, serum; alkaline phosphatase, serum; aspartate aminotransferase (AST/SGOT); bilirubin, direct; bilirubin, total; protein, total, serum
Note: Confirmation testing is performed on reactive results only if initial values fall within a designated range requiring additional confirmation.
Patient Instructions:
Some tests in this panel may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H or coenzyme R). Patient should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
Categories:
STD’s detection & monitoring,
Infectious diseases,
Liver diseases,
Price:
$133
|
|
Hepatitis Be Antibody
*Build Your Own Panel Eligible [?]
|
$175
|
|
|
Description:
Differential diagnosis, staging, and prognosis of hepatitis B infection. HBeAb appears in the early convalescence of HBV infection. With carrier state and chronic hepatitis, HBeAb may not develop.
The appearance of anti-HBe in patients who have previously been HBeAg positive indicates a reduced risk of infectivity. Failure of appearance implies disease activity and probable chronicity but patients with HBeAb may have chronic hepatitis. Chronic HBsAg carriers can be positive for either HBeAg or anti-HBe, but are less infectious when anti-HBe is present. HBe can persist for years, but usually disappears earlier than anti-HBs or anti-HBc. Anti-HBe has not been found as the sole serologic marker for hepatitis B infection.
A significant deviation from the normal range may require further evaluation by your phyisician.
Alternative Names(s): HBe Antibody, Anti-Hepatitis Be, HBeAb
Includes:
Hepatitis Be Antibody
Patient Instructions:
Some tests in this panel may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H or coenzyme R). Patient should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
Categories:
Liver diseases,
Price:
$175
|
|
Hepatitis Be Antigen
*Build Your Own Panel Eligible [?]
|
$140
|
|
|
Description:
HBeAg indicates active HBV replication. Infectivity is evaluated based on HBeAg and HBsAg. When HBeAg persists much longer than 10 weeks, the patient is likely to develop chronic hepatitis and be a carrier.
A significant deviation from the normal range may require further evaluation by your phyisician.
Alternative Names(s): HBe Antigen, HBeAg
Includes:
Hepatitis Be Antigen, serum.
Patient Instructions:
Some tests in this panel may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H or coenzyme R). Patient should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
Categories:
Liver diseases,
Price:
$140
|
|
Hepatitis Be Panel
*Build Your Own Panel Eligible [?]
|
$279
|
|
Description:
- Check hepatitis B infection activity
- Screen for viral contagiousness risk
- Monitor liver health over time
Categories:
Price:
$279
|
|
Hepatitis B Profile
|
$126
|
|
|
Description:
Hepatitis B is a liver disease that is caused by the hepatitis B virus (HBV). Hepatitis B is a bloodborne pathogen and exposure to the blood of an infected person may result in infection.
Abnormal results may require further evaluation by your physician.
Each marker in this panel provides valuable information about the stage of infection, the presence of the virus, and the person's immune response. Brief overview:
- Hepatitis B surface antigen (HBsAg): This is the primary marker for diagnosing Hepatitis B infection. Its presence indicates active viral replication and ongoing infection.
- Hepatitis B surface antibody (anti-HBs): This indicates immunity to Hepatitis B, either from past infection or vaccination. It's particularly useful in assessing immune protection against the virus.
- Hepatitis B core antibody (anti-HBc): This antibody indicates past or ongoing Hepatitis B infection. Its presence, along with other markers, can help differentiate between acute and chronic infection.
There isn't a single "best" marker for diagnosing Hepatitis B because different markers serve different purposes in diagnosing and managing the infection.
Includes:
Hep B Core Antibody, IgM Hepatitis B Surface Antibody Test Hepatitis B Surface Antigen (HBsAg) with Reflex Confirmation
Note: Confirmation testing is performed on reactive results only if initial values fall within a designated range requiring additional confirmation.
Patient Instructions:
Some tests in this panel may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H or coenzyme R). Patient should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
Categories:
STD’s detection & monitoring,
Infectious diseases,
Liver diseases,
Price:
$126
|
|
Hepatitis B Surface Antibody Level, Pre/Post HBIG Infusion
*Build Your Own Panel Eligible [?]
|
$344
|
|
Description:
- Checks immunity to Hepatitis B.
- Measures protection after HBIG shot.
- Assesses Hepatitis B vaccine response.
Includes:
Hepatitis B Surface Antibody Level, Pre/Post HBIG Infusion
Categories:
Price:
$344
|
|
Hepatitis B Surface Antibody, Qualititative
*Build Your Own Panel Eligible [?]
|
$71
|
|
|
Description:
The detection of anti-HBs is indicative of a prior immunologic exposure to the antigen or vaccine. To determine immune status as ≥10 mIU/mL as per CDC guidelines, please order Hepatitis B Surface Antibody, Quantitative.
Includes:
Hepatitis B Surface Antibody, Qualititative
Categories:
Infectious diseases,
Liver diseases,
Blood and blood diseases,
STD’s detection & monitoring,
Price:
$71
|
|
Hepatitis B Surface Antibody Test
*Build Your Own Panel Eligible [?]
|
$105
|
|
|
Description:
This assay is used to determine immune status for Hepatitis B as ¡Ý10 mIU/mL as per CDC Guidelines. Hepatitis B is a liver disease that is caused by the hepatitis B virus (HBV). Hepatitis B is a bloodborne pathogen and exposure to the blood of an infected person may result in infection.
Abnormal results may require further evaluation by your physician.
Presence of anti-HBs is an indicator of clinical recovery and subsequent immunity to hepatitis B virus. This test is useful for evaluation of possible immunity in individuals who are at increased risks for exposure to the hepatitis B (ie, hemodialysis unit personnel, venipuncturists, etc). Evaluate the need for hepatitis B immune globulin after needlestick injury; evaluate the need for hepatitis B vaccine and follow immune status after hepatitis B vaccine.
Includes:
Hepatitis B Surface Antibody Immunity, Quantitative
Categories:
STD’s detection & monitoring,
Liver diseases,
Infectious diseases,
Immunization blood testing,
Price:
$105
|
|
Hepatitis B Surface Antigen (HBsAg) with Reflex Confirmation
*Build Your Own Panel Eligible [?]
|
$59
|
|
|
Description:
Hepatitis B surface antigen is the earliest indicator of the presence of acute infection. Also indicative of chronic infection. Test is useful in the differential diagnosis of hepatitis. Patients who are negative for HBsAg may still have acute type B viral hepatitis. There is sometimes a core window stage when HBsAg has become negative and the patient has not yet developed the antibody (anti-HBs). In cases with strong clinical suspicion of viral hepatitis, serologic testing should not be limited to detecting HBsAg, but should include a battery of tests to evaluate different stages of acute and convalescent hepatitis.
Includes:
Hepatitis B Surface Antigen with Reflex Confirmation.
Positive samples will be confirmed based on the manufacturer's FDA approved recommendations.
Note: Confirmation testing is performed on reactive results only if initial values fall within a designated range requiring additional confirmation.
Patient Instructions:
Some tests in this panel may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H or coenzyme R). Patient should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
Categories:
Liver diseases,
General wellness,
Price:
$59
|
|
Hepatitis B Surface Antigen, Quantitative, Monitoring (Not for Diagnosis)
*Build Your Own Panel Eligible [?]
|
$785
|
|
|
Description:
Quantitative measurement of HBsAg may be used to confirm ongoing HBV replication and monitor responses to antiviral therapy. Published studies support the viewpoint that repeatedly low to undetectable HBsAg values are a good predictor of sustained viral clearance. This test should be used on individuals previously diagnosed with hepatitis B infection by qualitative HBsAg testing.
Categories:
Price:
$785
|
|
Hepatitis B Virus DNA, Quantitative, PCR with Reflex to HBV, Genotype
*Build Your Own Panel Eligible [?]
|
$727
|
|
|
Description:
This test is intended for use in conjunction with clinical presentation and other laboratory markers for the clinical management of patients with chronic HBV infection undergoing antiviral therapy. The test can be used to measure HBV DNA levels at baseline and during treatment to aid in assessing response to treatment.The cobas® HBV Test is not intended for use as a screening test for the presence of HBV in blood products or as a diagnostic test to confirm the presence of HBV infection.Reportable range is 10 to 1,000,000,000 IU/mL(1.00 to 9.00 Log IU/mL).(1.00 Log IU/mL to 9.00 Log IU/mL).
Categories:
Price:
$727
|
|
Hepatitis B Virus DNA, Quantitative, Real-Time PCR
*Build Your Own Panel Eligible [?]
|
$700
|
|
Description:
- Measures hepatitis B virus levels
- Detects active hepatitis B infection
- Monitors treatment effectiveness for hepatitis B
Includes:
Hepatitis B Virus DNA, Quantitative, Real-Time PCR
Categories:
Price:
$700
|
|
Hepatitis B Virus Drug Resistance, Genotype, and BCP/Precore Mutations
*Build Your Own Panel Eligible [?]
|
$889
|
|
|
Description:
This test is used to: 1. Identify HBV genotype (A-H) for epidemiology or prognostic purposes. 2. Detect hepatitis B virus (HBV) mutations associated with resistance to antiviral agents.
Categories:
Price:
$889
|
|
Hepatitis C Antibody with Reflex
*Build Your Own Panel Eligible [?]
|
$80
|
|
|
Description:
Hepatitis C is a liver disease that is caused by the hepatitis C virus (HCV). Hepatitis C is a bloodborne disease and exposure to the blood of an infected person may result in infection.
Hepatitis C Virus (HCV) is the major cause of hepatitis. Approximately 1% of blood donors are seropositive for anti-HCV. The clinical symptoms of a HCV infection are variable. Exposure to HCV results in a chronic infection in 50 to 80% of cases. The "window" between infection and seroreactivity is highly variable, up to 12 months.
Abnormal results may require further evaluation by your physician.
Includes:
Hepatitis C Antibody with confirmation reflex
****Hepatitis C Antibody Test is included in the Hep B and C Profile Test, and the Hepatitis Panel Acute w/Ref
Note: Confirmation testing is performed on reactive results only if initial values fall within a designated range requiring additional confirmation.
Categories:
Infectious diseases,
STD’s detection & monitoring,
Liver diseases,
Price:
$80
|
|
Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
*Build Your Own Panel Eligible [?]
|
$49
|
|
|
Description:
Hepatitis C Virus (HCV) is the major cause of hepatitis. Making positive HCV Ab tests reflex to confirmatory molecular testing is necessary to confirm active HCV infection. Providing a second reflex to perform genotyping on HCV isolates when RNA is detected is also a necessary step before starting therapy. This double reflex will reduce the percentage of antibody-positive patients who lack appropriate confirmatory RNA testing and who do not have genotype testing performed.
Categories:
Price:
$49
|
|
Hepatitis C Antibody with Reflex to HCV, RNA, Quantitative, Real-Time PCR
*Build Your Own Panel Eligible [?]
|
$74
|
|
Description:
- Checks for Hepatitis C infection.
- Identifies Hepatitis C virus presence.
- Measures Hepatitis C virus levels.
Includes:
Hepatitis C Antibody with Reflex to HCV, RNA, Quantitative, Real-Time PCR
Categories:
Price:
$74
|
|
Hepatitis C-Infected Patient, Baseline Panel 1
*Build Your Own Panel Eligible [?]
|
$963
|
|
|
Description:
This panel is important to baseline the laboratory parameters in order to define change on therapy as well as to assess the risk of any underlying medical conditions prior to initiation of therapy for Hepatitis C.
Categories:
Price:
$963
|
|
Hepatitis C-Infected Patient, Baseline Panel 2
*Build Your Own Panel Eligible [?]
|
$907
|
|
|
Description:
This panel is useful in assessing the risk of any underlying medical conditions prior, during, and after initiation of therapy for Hepatitis C. This baseline profile does not include Hepatitis A or Hepatitis B testing, under the assumption this testing has already been performed. If these tests are desired, consider using 91704 (Hepatitis C-Infected Patient, Baseline Panel 1) or ordering separately. The relevant laboratory monitoring has been defined in the most recent AASLD guidelines.
Categories:
Price:
$907
|
|
Hepatitis C-Infected Patient, Treatment Panel
*Build Your Own Panel Eligible [?]
|
$908
|
|
|
Description:
Hepatitis C patients should be monitored during therapy to assess both response to therapy as well as evaluation for side effects.
Categories:
Price:
$908
|
|
Hepatitis C Viral RNA Genotype 1 NS3 Drug Resistance
*Build Your Own Panel Eligible [?]
|
$1342
|
|
|
Description:
This assay may be used to detect grazoprevir, simeprevir and paritaprevir resistance-associated NS3 mutations in genotype 1 NS3 protease inhibitor treatment-experienced patients and also the Q80K polymorphism in patients being considered for a simeprevir-containing regimen.
Categories:
Price:
$1342
|
|
Hepatitis C Viral RNA Genotype 1 NS5a Drug Resistance
*Build Your Own Panel Eligible [?]
|
$1342
|
|
|
Description:
For detection of mutations in the NS5a gene associated with resistance to NS5a inhibitors (examples: daclatasvir, ledipasvir, ombitasvir, elbasvir and velpatasvir). Testing for NS5a resistance-associated variants prior to initiation of treatment with elbasvir plus grazoprevir in HCV genotype 1a infected patients is recommended.
Categories:
Price:
$1342
|
|
Hepatitis C Viral RNA Genotype 1 NS5b Drug Resistance
*Build Your Own Panel Eligible [?]
|
$1342
|
|
|
Description:
For detection of mutations in the Genotype 1 NS5b gene associated with resistance to nucleotide analog NS5b polymerase inhibitors (example: sofosbuvir, a nucleotide analog inhibitor of HCV NS5b polymerase).
Categories:
Price:
$1342
|
|
Hepatitis C Viral RNA Genotype 3 NS5a Drug Resistance
*Build Your Own Panel Eligible [?]
|
$1342
|
|
|
Description:
For detection of mutations in the genotype 3 NS5a gene associated with resistance to NS5a inhibitors (example: daclatasvir, velpatasvir) including the Y93H polymorphism.
Categories:
Price:
$1342
|
|
Hepatitis C Viral RNA, Quantitative Real-Time PCR
*Build Your Own Panel Eligible [?]
|
$865
|
|
|
Description:
Hepatitis C is a liver disease that is caused by the hepatitis C virus (HCV). Hepatitis C is a bloodborne disease and exposure to the blood of an infected person may result in infection.
This test is used to detect and confirm hepatitis C virus infection.
Abnormal results may require further evaluation by your physician.
Includes:
Hepatitis C Viral RNA, Quantitative Real-Time PCR
Estimated turnaround for results is 9 business days.
Categories:
STD’s detection & monitoring,
Infectious diseases,
Liver diseases,
Price:
$865
|
|
Hepatitis C Viral RNA, Quantitative, Real-Time PCR
*Build Your Own Panel Eligible [?]
|
$865
|
|
Description:
- Measures Hepatitis C virus levels.
- Detects active Hepatitis C infection.
- Tracks response to Hepatitis C treatment.
Categories:
Price:
$865
|
|
Hepatitis C Viral RNA, Quantitative Real-Time PCR with Reflexes
*Build Your Own Panel Eligible [?]
|
$900
|
|
|
Description:
Hepatitis C (HCV) viral genotype may be required to select the most appropriate direct acting agent(s) (DAA) in the treatment of hepatitis C. Refer to the FDA package inserts of the relevant DAA's and to the AASLD and IDSA Recommendations for Testing, Managing and Treating Hepatitis C (https://www.hcvguidelines.org/). This reflex code offers clinicians the option to obtain the HCV Viral load, HCV genotype and NS5a resistance testing with a single test order when considering treatment in circumstances where all three tests are warranted.
Categories:
Price:
$900
|
|
Hepatitis C Virus RNA Genotype
*Build Your Own Panel Eligible [?]
|
$879
|
|
|
Description:
Determination of hepatitis C genotype is often required to select the most appropriate direct acting agent(s) (DAA) for the treatment of hepatitis C. Some DAA's are only effective for the treatment of hepatitis C genotype 1, whereas others may be used for additional genotypes. A concurrent patient HCV viral load of ≥2000 IU/mL is required for this test.
Categories:
Price:
$879
|
|
Hepatitis C Virus RNA Genotype with Reflex to HCV NS5a Drug Resistance
*Build Your Own Panel Eligible [?]
|
$879
|
|
|
Description:
Determination of hepatitis C genotype is often required to select the most appropriate direct acting agent(s) (DAA) for the treatment of hepatitis C. Some DAA's are only effective for the treatment of hepatitis C genotype 1, whereas others may be used for additional genotypes. A concurrent patient HCV viral load of ≥2000 IU/mL is required for this test.
Categories:
Price:
$879
|
|
Hepatitis C Virus RNA, Quantitative Real-Time PCR with Reflex to Genotype
*Build Your Own Panel Eligible [?]
|
$900
|
|
|
Description:
Useful in monitoring response to therapy and/or disease progression. Reportable range is 15 to 100,000,000 IU/mL (1.18-8.00 log IU/mL).
Categories:
Price:
$900
|
|
Hepatitis D Virus (HDV) Antibody (IgM)
*Build Your Own Panel Eligible [?]
|
$492
|
|
|
Description:
Hepatitis D Virus (HDV) infection occurs only in association with Hepatitis B Virus (HBV) infection. A positive result for HDV IgM indicates either recent HDV infection or chronic HDV infection with IgM persistence.
Categories:
Price:
$492
|
|
Hepatitis D Virus (HDV) Antibody, Total
*Build Your Own Panel Eligible [?]
|
$327
|
|
|
Description:
Hepatitis D Virus (HDV) infection occurs only in association with Hepatitis B Virus (HBV) infection. A positive result for HDV total antibody may indicate acute infection, chronic infection, or past infection with recovery.
Categories:
Price:
$327
|
|
Hepatitis D Virus (HDV) Antibody, Total with Reflex to HDV, Real-Time PCR
*Build Your Own Panel Eligible [?]
|
$327
|
|
|
Description:
Hepatitis D Virus (HDV) infection occurs only in association with Hepatitis B Virus (HBV) infection. A positive result for HDV total antibody may indicate acute infection, chronic infection, or past infection with recovery.
Categories:
Price:
$327
|
|
Hepatitis D Virus RNA, Qualitative, Real-Time PCR
*Build Your Own Panel Eligible [?]
|
$724
|
|
|
Description:
Hepatitis D Virus (HDV) is an RNA virus whose transmission is dependent on associated hepatitis B viral infection.
Categories:
Price:
$724
|
|
Hepatitis D Virus RNA, Quantitative Real-Time PCR
*Build Your Own Panel Eligible [?]
|
$1172
|
|
|
Description:
Hepatitis D virus (HDV) infection requires the surface antigen from HBV and may occur as an acute infection with HBV or as a superinfection of a chronic HBV infection. HDV should be considered in any individual who tests positive for the HBV surface antigen (HBsAg). The presence of HDV RNA in the serum reflects viral replication in the liver. HDV-HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression towards liver-related death and hepatocellular carcinoma. HDV RNA, quantitative real-time PCR can assist with diagnosis of HDV infection as well as monitoring of treatment.
Categories:
Price:
$1172
|
|
Hepatitis E Virus (HEV) Antibodies (IgG, IgM)
*Build Your Own Panel Eligible [?]
|
$393
|
|
|
Description:
This test is intended for the qualitative detection of antibodies against Hepatitis E virus (HEV). HEV causes acute viral hepatitis and liver injury worldwide, although it is not commonly acquired in the United States. Diagnosis of acute infection can be achieved through the detection of IgM, whereas IgG may represent remote or past exposure. This test does not detect antibodies against other hepatitis-causing viruses, including Hepatitis A, B, or C.HEV is transmitted via the fecal-oral route, most commonly by consumption of contaminated water or undercooked meat. Signs and symptoms of HEV are similar to other causes of acute viral hepatitis and may include fever, fatigue, nausea, vomiting, jaundice, and dark urine. The disease can be mild and self-limiting, and most individuals recover from illness. Immunocompromised individuals, those with underlying liver conditions, and pregnant women are at increased risk for severe disease, including fulminant hepatitis. Testing is recommended in patients with viral hepatitis symptoms who have traveled to an endemic or outbreak area and/or have tested negative for other etiologies (Hepatitis A, Hepatitis B, Hepatitis C, other hepatotropic viruses, and causes of acute liver injury).Antibodies against HEV can typically be detected within 3-4 weeks after exposure. Anti-IgM declines during early convalescence and may be negative a few months post- exposure while anti-IgG can persist for years. Results should be correlated with patient risk factors and signs and symptoms consistent with Hepatitis E. False positive results can occur in low prevalence populations. False negative results can occur early during infection. If there is a high clinical suspicion for HEV, repeat testing can be performed in 2-4 weeks.References1. Q&As for Health Professionals, Viral Hepatitis, Centers for Disease Control and Prevention.https://www.cdc.gov/hepatitis/hev/hevfaq.htm Page last reviewed: September 15, 2020.2. Hepatitis E, World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hepatitis-e Last updated: 20 July 2023.3. Aggarwal, R. et al. Diagnosis of hepatitis E. Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):24-33.4. American Academy of Pediatrics, Red Book 2018-2021. Report of the Committee of Infectious Diseases, 31st Edition.
Categories:
Price:
$393
|
|
Hepatitis E Virus (HEV) Antibody (IgG)
*Build Your Own Panel Eligible [?]
|
$288
|
|
|
Description:
This test is intended for the qualitative detection of antibodies against Hepatitis E virus (HEV). HEV causes acute viral hepatitis and liver injury worldwide, although it is not commonly acquired in the United States. Diagnosis of acute infection can be achieved through the detection of IgM, whereas IgG may represent remote or past exposure. This test does not detect antibodies against other hepatitis-causing viruses, including Hepatitis A, B, or C.HEV is transmitted via the fecal-oral route, most commonly by consumption of contaminated water or undercooked meat. Signs and symptoms of HEV are similar to other causes of acute viral hepatitis and may include fever, fatigue, nausea, vomiting, jaundice, and dark urine. The disease can be mild and self-limiting, and most individuals recover from illness. Immunocompromised individuals, those with underlying liver conditions, and pregnant women are at increased risk for severe disease, including fulminant hepatitis. Testing is recommended in patients with viral hepatitis symptoms who have traveled to an endemic or outbreak area and/or have tested negative for other etiologies (Hepatitis A, Hepatitis B, Hepatitis C, other hepatotropic viruses, and causes of acute liver injury).Antibodies against HEV can typically be detected within 3-4 weeks after exposure. Anti-IgM declines during early convalescence and may be negative a few months post- exposure while anti-IgG can persist for years. Results should be correlated with patient risk factors and signs and symptoms consistent with Hepatitis E. False positive results can occur in low prevalence populations. False negative results can occur early during infection. If there is a high clinical suspicion for HEV, repeat testing can be performed in 2-4 weeks.References1. Q&As for Health Professionals, Viral Hepatitis, Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis/hev/hevfaq.htm Page last reviewed: September 15, 2020.2. Hepatitis E, World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hepatitis-e Last updated: 20 July 2023.3. Aggarwal, R. et al. Diagnosis of hepatitis E. Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):24-33.4. American Academy of Pediatrics, Red Book 2018-2021. Report of the Committee of Infectious Diseases, 31st Edition.
Categories:
Price:
$288
|
|
Hepatitis E Virus (HEV) Antibody (IgM)
*Build Your Own Panel Eligible [?]
|
$329
|
|
|
Description:
This test is intended for the qualitative detection of antibodies against Hepatitis E virus (HEV). HEV causes acute viral hepatitis and liver injury worldwide, although it is not commonly acquired in the United States. Diagnosis of acute infection can be achieved through the detection of IgM, whereas IgG may represent remote or past exposure. This test does not detect antibodies against other hepatitis-causing viruses, including Hepatitis A, B, or C.HEV is transmitted via the fecal-oral route, most commonly by consumption of contaminated water or undercooked meat. Signs and symptoms of HEV are similar to other causes of acute viral hepatitis and may include fever, fatigue, nausea, vomiting, jaundice, and dark urine. The disease can be mild and self-limiting, and most individuals recover from illness. Immunocompromised individuals, those with underlying liver conditions, and pregnant women are at increased risk for severe disease, including fulminant hepatitis. Testing is recommended in patients with viral hepatitis symptoms who have traveled to an endemic or outbreak area and/or have tested negative for other etiologies (Hepatitis A, Hepatitis B, Hepatitis C, other hepatotropic viruses, and causes of acute liver injury).Antibodies against HEV can typically be detected within 3-4 weeks after exposure. Anti-IgM declines during early convalescence and may be negative a few months post-exposure while anti-IgG can persist for years. Results should be correlated with patient risk factors and signs and symptoms consistent with Hepatitis E. False positive results can occur in low prevalence populations. False negative results can occur early during infection. If there is a high clinical suspicion for HEV, repeat testing can be performed in 2-4 weeks.References1. Q&As for Health Professionals, Viral Hepatitis, Centers for Disease Control and Prevention. www.cdc.gov/hepatitis/hev/hevfaq.htm Page last reviewed: September 15, 2020.2. Hepatitis E, World Health Organization. www.who.int/news-room/fact-sheets/detail/hepatitis-e Last updated: 20 July 20233. Aggarwal, R. et al. Diagnosis of hepatitis E. Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):24-33.4. American Academy of Pediatrics, Red Book 2018-2021. Report of the Committee of Infectious Diseases, 31st Edition
Categories:
Price:
$329
|
|
Hepatitis Panel Acute, w/ Ref Confirmation
*Build Your Own Panel Eligible [?]
|
$289
|
|
|
Description:
Hepatitis is a disease of the liver causing inflammation. The Hepatitis Profile detects hepatitis A (HAV), hepatitis B (HBV) and hepatitis C (HCV) infections.
Abnormal results may require further evaluation by your physician.
Alternative Name(s): Acute Hepatitis Panel with Reflex
Includes:
Hepatitis A IgM (Acute),
Hepatitis B Surface Antigen
Hepatitis B Core IgM Antibody,
Hepatitis C Antibody
Note: Confirmation testing is performed on reactive results only if initial values fall within a designated range requiring additional confirmation.
Categories:
Infectious diseases,
Liver diseases,
STD’s detection & monitoring,
Price:
$289
|
|
Hepatitis Panel, General
*Build Your Own Panel Eligible [?]
|
$198
|
|
|
Description:
This panel provides information on infection and the immune response to hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV), the 3 most common causes of viral hepatitis in the United States. In patients with unexplained elevated liver enzyme levels, this panel may be helpful in evaluating etiology for these viral hepatitides [1-4].This panel includes 5 tests with reflexes: total HAV antibody, qualitative hepatitis B surface antibody (HBsAb), hepatitis B surface antigen (HBsAg) with reflex confirmation, total hepatitis B core antibody (HBcAb), and HCV antibody with reflex to HCV RNA quantitative real-time PCR. The section below outlines the roles of the analytes assessed with this panel.Total HAV antibody: Presence of total HAV antibody is consistent with (1) immunity due to prior infection or vaccination; or (2) current HAV infection or recent HAV vaccination [2].Qualitative HBsAb: Presence indicates resolution of HBV infection or prior vaccination. To determine immune status due to past HBV infection or vaccination (ie, HBsAb titer ≥10 mIU/mL), a quantitative HBsAb test must be ordered [3].HBsAg with reflex confirmation: Presence indicates that a person has a current HBV infection and is infectious [3].Total HBcAb: Presence indicates past or current HBV infection [3].HCV antibody with reflex to HCV RNA: Presence (with detectable HCV RNA) indicates current infection. A positive result with a "not detected" HCV RNA reflex result may indicate a resolved infection or a biological false-positive antibody screening test [4].The results of the test in the panel should be interpreted in the context of pertinent clinical history and physical examination findings.References1. Viral Hepatitis Surveillance - United States, 2019. Centers for Disease Control and Prevention. Accessed January 16, 2022. https://www.cdc.gov/hepatitis/statistics/2019surveillance/pdfs/2019HepSurveillanceRpt.pdf2. Nelson NP, et al. MMWR Recomm Rep. 2020;69(5):1-38.3. Roush SW, et al. Chapter 22: laboratory support for surveillance of vaccine-preventable diseases. In: Roush SW, et al, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. Centers for Disease Control and Prevention. Reviewed June 3, 2021. Accessed January 16, 2022. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt22-lab-support.html4. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2013;62(18):362-365.
Categories:
Price:
$198
|
|
Hepatocellular Carcinoma Panel
*Build Your Own Panel Eligible [?]
|
$513
|
|
|
Description:
HCC Risk Panel includes serum AFP-L3%, total AFP and DCP. The combined measurement helps discriminate benign and malignant conditions related to primary liver diseases [1-4]. Furthermore, the combination measurement of three HCC biomarkers can identify a greater number of patients at risk of developing HCC than with each marker alone.
Categories:
Price:
$513
|
|
Hep B Core Antibody, IgM
*Build Your Own Panel Eligible [?]
|
$73
|
|
|
Description:
Hepatitis B is a liver disease that is caused by the hepatitis B virus (HBV). Hepatitis B is a bloodborne pathogen and exposure to the blood of an infected person may result in infection.
Hepatitis B core-specific IgM class antibody has been detected in most acute infections and is a reliable marker for acute disease. In some cases, hepatitis B core IgM antibody may be the only specific marker for the diagnosis of acute infection with hepatitis B virus.
Abnormal results may require further evaluation by your physician.
Includes:
Hep B Core Antibody, IgM
Alternative Name(s):
Anti-HBc, IgM
****Hepatitis B Core Antibody, IgM is included in the Hep B and C Profile Test.****
Categories:
Infectious diseases,
STD’s detection & monitoring,
Liver diseases,
Price:
$73
|
|
HER-2, IHC with Interpretation
*Build Your Own Panel Eligible [?]
|
$616
|
|
Description:
- Check tumor HER-2 protein status
- Guide targeted cancer treatment decisions
- Confirm unclear prior test results
Categories:
Price:
$616
|
|
HER-2, IHC, without Interpretation
*Build Your Own Panel Eligible [?]
|
$593
|
|
Description:
- Check tumor tissue protein levels
- Assess cancer cell growth markers
- Screen biopsy samples for HER-2
Categories:
Price:
$593
|
|
HER-2, IHC with Reflex to FISH
*Build Your Own Panel Eligible [?]
|
$616
|
|
|
Description:
HER-2/NEU expression is commonly performed on breast carcinomas. Women who have tumors that overexpress HER-2/NEU are most likely to be responsive to monoclonal antibody therapy directed against this target.
Categories:
Price:
$616
|
|
Hereditary Breast Cancer Panel
*Build Your Own Panel Eligible [?]
|
$4519
|
|
|
Description:
The Hereditary Breast Cancer Panel includes 18 genes associated primarily with hereditary breast and possibly other cancers. This can include, but is not limited to, cancers of the breast, colon, endometrium, stomach, urinary tract, ovary, pancreas, prostate, and other tissues. Individuals with a positive result (pathogenic or likely pathogenic variant detected) have an increased risk for developing certain cancers relative to that of the general population.
Categories:
Price:
$4519
|
|
Hereditary Colorectal Cancer Panel
*Build Your Own Panel Eligible [?]
|
$4584
|
|
|
Description:
The Hereditary Colorectal Cancer Panel includes 20 genes associated primarily with hereditary gastrointestinal cancers and possibly other cancers. This can include, but is not limited to, cancers of the colon, endometrium, stomach, urinary tract, ovary, pancreas, prostate, and rectum. Individuals with a positive result (pathogenic or likely pathogenic variant detected) have an increased risk for developing certain cancers relative to that of the general population.
Categories:
Price:
$4584
|
|
Hereditary Endocrine Cancer Panel
*Build Your Own Panel Eligible [?]
|
$1733
|
|
|
Description:
The Hereditary Endocrine Cancer Panel includes 12 genes associated with hereditary cancers of the endocrine system. This can include, but is not limited to, cancers of the neuroendocrine system, kidneys, thyroid, adrenal glands, paraganglia, and other tissues. Individuals with a positive result (pathogenic or likely pathogenic variant detected) have an increased risk for developing certain cancers relative to that of the general population.
Categories:
Price:
$1733
|
|
Herpes Simplex Virus 1 and 2 (IgG), with Reflex to HSV-2 Inhibition
*Build Your Own Panel Eligible [?]
|
$133
|
|
|
Description:
Herpes Simplex Virus 1 and 2 (IgG), with Reflex to HSV-2 Inhibition - Herpes Simplex Virus (HSV) is responsible for several clinically significant human viral diseases, with severity ranging from inapparent to fatal. Clinical manifestations include genital tract infections, neonatal herpes, meningoencephalitis, keratoconjunctivitis, and gingivostomatitis. There are two HSV serotypes that are closely related antigenically. HSV type 2 is more commonly associated with genital tract and neonatal infections, while HSV type 1 is more commonly associated with infections of non-genital sites. Specific typing is not usually required for diagnosis or treatment. The mean time to seroconversion using the type specific assay is 25 days. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, or for testing of immunocompromised patients.
This assay utilizes recombinant type-specific antigens to differentiate HSV-1 from HSV-2 infections. A index positive result cannot distinguish between recent and past infection. If recent HSV infection is suspected but the results are negative or equivocal, the assay should be repeated in 4-6 weeks.
Confirmation testing with HSV-2 Inhibition on positive initial results vs the Western Blot:
The HSV-2 IgG Western blot assay has historically been considered the gold standard for identifying HSV-2 IgG reactivity. However, Ashley-Morrow et al have clearly demonstrated that the HSV-2 IgG Western blot is less sensitive than the HerpeSelect HSV-2 IgG assay for detecting IgG seroconversion following newly acquired HSV-2 infection: the median interval between symptom onset and IgG seroconversion is 21 days for the HerpeSelect assay versus 68 days for the Western blot assay.3 There is thus a window of approximately 47 days in which the Western blot assay may give false-negative confirmatory results. In contrast, true-positive specimens in this window are positive (>60% inhibition) in the HSV-2 IgG inhibition assay. In addition to increased sensitivity, the turnaround time for the inhibition assay is shorter than that of the Western blot assay.
Includes:
HSV 1 IgG, Type Specific Ab HSV 2 IgG, Type Specific Ab
If Herpes Simplex Virus 2 (IgG) is >1.09, then HSV-2 Inhibition Study will be performed and turnaround time could be up to 7 business days.
Categories:
STD’s detection & monitoring,
Price:
$133
|
|
Herpes Simplex Virus 1 (IgG), Type-Specific Antibody
*Build Your Own Panel Eligible [?]
|
$59
|
|
Description:
- Checks for past herpes type 1.
- Detects herpes antibodies in blood.
- Identifies long-term herpes infection.
Includes:
Herpes Simplex Virus 1 (IgG), Type-Specific Antibody
Categories:
Price:
$59
|
|
Herpes Simplex Virus 2 (IgG), with Reflex to HSV-2 Inhibition
*Build Your Own Panel Eligible [?]
|
$119
|
|
|
Description:
Herpes Simplex Virus 2 (IgG), with Reflex to HSV-2 Inhibition - Herpes Simplex Virus (HSV) is responsible for several clinically significant human viral diseases, with severity ranging from inapparent to fatal. Clinical manifestations include genital tract infections, neonatal herpes, meningoencephalitis, keratoconjunctivitis, and gingivostomatitis. There are two HSV serotypes that are closely related antigenically. HSV type 2 is more commonly associated with genital tract and neonatal infections, while HSV type 1 is more commonly associated with infections of non-genital sites. Specific typing is not usually required for diagnosis or treatment. The mean time to seroconversion using the type specific assay is 25 days. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, or for testing of immunocompromised patients.
If recent HSV infection is suspected but the results are negative or equivocal, the assay should be repeated in 4-6 weeks.
Confirmation testing with HSV-2 Inhibition on positive initial results vs the Western Blot:
The HSV-2 IgG Western blot assay has historically been considered the gold standard for identifying HSV-2 IgG reactivity. However, Ashley-Morrow et al have clearly demonstrated that the HSV-2 IgG Western blot is less sensitive than the HerpeSelect HSV-2 IgG assay for detecting IgG seroconversion following newly acquired HSV-2 infection: the median interval between symptom onset and IgG seroconversion is 21 days for the HerpeSelect assay versus 68 days for the Western blot assay.3 There is thus a window of approximately 47 days in which the Western blot assay may give false-negative confirmatory results. In contrast, true-positive specimens in this window are positive (>60% inhibition) in the HSV-2 IgG inhibition assay. In addition to increased sensitivity, the turnaround time for the inhibition assay is shorter than that of the Western blot assay.
Includes:
Herpes Simplex Virus 2 (IgG)
If Herpes Simplex Virus 2 (IgG) >1.09, then HSV-2 Inhibition Study will be performed
Categories:
STD’s detection & monitoring,
Price:
$119
|
